Clinical Takeaway
Trauma-focused treatments remain effective for PTSD even when patients are actively using cannabis, including those with co-occurring substance use disorders. Clinicians should not withhold or delay evidence-based PTSD care based on a patient’s cannabis use status.
#6 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis directly addresses a critical clinical gap by evaluating whether gold-standard trauma-focused PTSD treatments remain efficacious in the substantial subset of patients with comorbid cannabis and other substance use disorders, a population often excluded from or underrepresented in efficacy trials. Understanding treatment outcomes across cannabis use patterns is essential for treatment planning and setting appropriate patient expectations, particularly given the high prevalence of cannabis use in PTSD populations. The findings inform whether current evidence-based protocols require modification or whether existing treatments can be reliably deployed across this complex, clinically common patient population.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
? While this meta-analysis addresses a clinically relevant question about whether trauma-focused treatments remain effective for patients with concurrent PTSD and cannabis use, several important limitations warrant cautious interpretation. The analysis draws from only four RCTs nested within a larger dataset, which substantially constrains statistical power and generalizability, particularly given the heterogeneity of cannabis use patterns, dosing, and frequency across study populations. The meta-analysis does not appear to distinguish between cannabis use as a primary substance of concern versus incidental use, nor does it clarify whether cannabis was actively used during treatment or merely present in the baseline clinical picture, both of which could meaningfully affect treatment response. From a practical standpoint, clinicians should continue offering evidence-based trauma-focused therapies to patients with PTSD and cannabis use, while remaining alert to potential interactions between active cannabis use and therapeutic engagement, and considering individualized assessment of whether cannabis is serving as self-medication for PTSD symptoms, which may require concurrent motivational or harm-reduction interventions.
| |
Have thoughts on this? Share it:
